Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b Trial Investigating the Pharmacokinetics and Safety Profile of a Single Intravenous Dose of rFXIII in Paediatric (1 to Less Than 6 Years Old) Subjects With Congenital FXIII A-subunit Deficiency

NCT01230021 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01230021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01230021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b Trial Investigating the Pharmacokinetics and Safety Profile of a Single Intravenous Dose of rFXIII in Paediatric (1 to Less Than 6 Years Old) Subjects With Congenital FXIII A-subunit Deficiency
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2010
Completion date
January 31, 2012
Enrollment
6 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

congenital bleeding disorder, congenital fxiii deficiency